DTU Logo
Overview | 4-T | ACE | ADOPT | AFORRD | DREAM | EDIT | EXSCEL | FHS | GLINT | ISAT | LDS | NAVIGATOR | TECOS | UKPDS

Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research

NAVIGATOR logo


Publications (4 of 24)


Search Publications :

2017

Updated risk factors should be used to predict development of diabetes
Mary Angelyn Bethel, Kristen A. Hyland, Antonio R. Chacra, Prakash Deedwania, Gregory R. Fulcher, Rury R. Holman, Trond Jenssen, Naomi S. Levitt, John J.V. McMurray, Eleni Boutati, Laine Thomas, Jie-Lena Sun, Steven M. Haffner for the NAVIGATOR Study Group
J Diabetes Complications 2017;31:859-863. Published:May-2017. Epub:02-Mar-2017. PMID:28319004. doi:10.1016/j.jdiacomp.2017.02.012

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial
Sharma A, de Souza Brito F2, Sun JL, Thomas L, Haffner S, Holman RR, Lopes RD
Am Heart J. 2017;186:73-82. Published:Apr-2017. Epub:29-Dec-2016. PMID:28454835. doi:10.1016/j.ahj.2016.12.011

International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance
Harumi Higuchi Dos Santos M, Sharma A, Sun JL, Pieper K, McMurray JJ, Holman RR, Lopes RD
J Am Heart Assoc 2017;6:e003892. Published:13-Jan-2017. Epub:13-Jan-2017. PMID:28087508. doi:10.1161/JAHA.116.003892

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance
Currie G, Angelyn Bethel M, Holzhauer B, Haffner SM, Holman RR, McMurray JJ
Diabetes Obes Metab. 2017;19:791-799. Epub:17-Jul-2017. PMID:28093841. doi:10.1111/dom.12877